Results 111 to 120 of about 34,211 (250)
Adjuvant systemic treatment in luminal breast cancer — what else apart from hormone therapy?
Oncology in Clinical PracticeThe luminal subtype [hormone receptor (HR) expression and absence of HER2 overexpression] occurs in more than 70% of patients with early breast cancer.
Sylwia Dębska-Szmich, Piotr Potemski
doaj +1 more source
VIEW, EarlyView.Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf +5 more
wiley +1 more source
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source
DNA unwinding and inhibition of T4 DNA ligase by anthracyclines
, 1988 The ability to alter DNA tertiary structure of ten anthracycline derivatives whose antitumor potency is known was studied by an assay that makes use of nicked circular DNA and bacteriophage T4 DNA ligase.
MONTECUCCO A. +4 more
core +1 more source
Pregnancy and Cardiomyopathy After Anthracyclines in Childhood
, 2018 With advances in cancer therapy, there has been a remarkable increase in survival in children diagnosed with malignancies. Many of these children are treated with anthracyclines which are well known to cause cardiotoxicity.
Kara Annette Thompson
core +1 more source
British Journal of Haematology, EarlyView.Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon +14 more
wiley +1 more source
Сибирский онкологический журналIntroduction. Detection of the cardiotoxic effect during chemotherapy (CT) for malignant neoplasms is one of the most important tasks of a practicing physician.
I. A. Karput +7 more
doaj +1 more source
, 2004 The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the treatment of many neoplastic diseases; on the other hand, chronic ...
Luca Gianni +9 more
core +1 more source
British Journal of Haematology, EarlyView.Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend +16 more
wiley +1 more source
, 2016 International audiencePurposePatients with metabolic syndrome have a greater risk of cardiovascular disease, although their susceptibility to chemotherapy-induced cardiac disease is not well documented.
Yu, Anthony, F +20 more
core +1 more source